



Article

# A Boolean Model of the Formation of Tumour Associated Macrophages in an *in-vitro* Model of Chronic Lymphocytic Leukaemia

Malvina Marku <sup>1,2\*</sup> , Flavien Raynal <sup>1,2</sup>, Nina Verstraete <sup>1,2</sup>, Marcin Domagala <sup>1,2</sup>, Miguel Madrid-Mencía <sup>1,2</sup>, Mary Poupot <sup>1,2</sup>, Jean-Jacques Fournié <sup>1,2</sup>, Loïc Ysebaert <sup>1,2,3</sup> and Vera Pancaldi <sup>1,2,4\*</sup> 

<sup>1</sup> INSERM, Centre de Recherches en Cancérologie de Toulouse: 2 Avenue Hubert Curien 31037, France

<sup>2</sup> Université III Toulouse Paul Sabatier: Route de Narbonne, 31330 Toulouse

<sup>3</sup> Service d'Hématologie, Institut Universitaire du Cancer de Toulouse-Oncopole, Toulouse, France

<sup>4</sup> Barcelona Supercomputing Center: Carrer de Jordi Girona, 29, 31, 08034 Barcelona, Spain

\* Correspondence: e-mail [malvina.marku@inserm.fr](mailto:malvina.marku@inserm.fr), [vera.pancaldi@inserm.fr](mailto:vera.pancaldi@inserm.fr); Tel.: +33 5-82-74-17-74 (FR)

Version October 13, 2020 submitted to *Cancers*

**Abstract:** The tumour microenvironment is the collection of cells in and surrounding cancer cells in a tumour including a variety of immune cells, especially neutrophils and monocyte-derived macrophages. In a tumour setting, macrophages encompass a spectrum between a tumour-suppressive (M1) or tumour-promoting (M2) state. The biology of macrophages found in tumours (Tumour Associated Macrophages) remains unclear, but understanding their impact on tumour progression is highly important. In this paper, we perform a comprehensive analysis of a macrophage polarization network, following two lines of enquiry: (i) we reconstruct the macrophage polarization network based on literature, extending it to include important stimuli in a tumour setting, and (ii) we build a dynamical model able to reproduce macrophage polarization in the presence of different stimuli, including the contact with cancer cells. Our simulations recapitulate the documented macrophage phenotypes and their dependencies on specific receptors and transcription factors, while also elucidating the formation of a special type of tumour associated macrophages in an *in-vitro* model of chronic lymphocytic leukaemia. This model constitutes the first step towards elucidating the cross-talk between immune and cancer cells inside tumours, with the ultimate goal of identifying new therapeutic targets that could control the formation of tumour associated macrophages in patients.

**Keywords:** Boolean model, tumour associated macrophage, macrophage polarization, Nurse Like Cells, Chronic Lymphocytic Leukaemia

## 1. Introduction

As all living cells, macrophages perceive and respond to intra- and extracellular signals in order to maintain their functions (endocytic, phagocytic and secretory, for example) by displaying a wide spectrum of specific phenotypes (polarizations) in different inducer environments. Based on their activity and the expression of specific proteins, markers and chemokines, two major subsets of macrophages have been identified, namely classically activated macrophages (M1) exhibiting a pro-inflammatory response, and alternatively activated macrophages (M2, themselves subdivided into 4 subclasses: M2a, M2b, M2c, M2d [1–3]) exhibiting an anti-inflammatory response. Additionally, multiple studies support the idea that M1 and M2 macrophages represent, in fact, the extremes of a continuous polarization spectrum of cells deriving from the differentiation of monocytes[4]. Macrophages have a plastic gene expression profile that is determined by the type, concentration and duration of exposure to the polarization stimuli in an inflammatory environment [3,5–8].

30 Macrophages are also found inside tumours, as part of the tumour micro-environment (TME), a  
31 complex ecology of cells that are found surrounding cancer cells including also other immune cells such  
32 as lymphocytes and neutrophils and other normal cells. In many tumours, infiltrated macrophages  
33 display mostly an M2-like phenotype, which provides an immunosuppressive microenvironment. In  
34 cancer, these *tumour associated macrophages (TAMs)* secrete several cytokines, chemokines and proteins  
35 which promote tumour angiogenesis, growth and metastasis [9–12]. Interestingly, it has been observed  
36 that, in established tumours, signals originating from cancer cells can cause phenotypic shifts in  
37 macrophages, leading to alternative functions that do not correspond to either M1 or M2 phenotypes  
38 [13]. Several studies have demonstrated that TAMs directly suppress CD8<sup>+</sup> T cell activation *in-vitro*  
39 [14–17]. Mechanisms that orchestrate this process, either directly or indirectly, remain unclear [18] and  
40 warrant further exploration due to macrophages' important impact on tumour progression.

41 In any given environment, the cellular processes that determine a cell's phenotype consist in a  
42 cascade of interactions, which can be represented as a *regulatory network*, in which nodes represent  
43 proteins, enzymes, chemokines, etc., while the connections represent the type (activation or inhibition)  
44 and direction of interactions of different types (transcriptional and post-translational activations).  
45 Network modelling has found numerous applications in studying the structure and dynamic behaviour  
46 of different biological systems in response to environmental stimuli and internal perturbations  
47 [19–22]. Several computational models of different pathways involved in the inflammatory immune  
48 response have been previously published, such as: continuous, logical and multi-scale model of T cell  
49 differentiation [23–25], logical models of macrophage differentiation in pro- and anti-inflammatory  
50 conditions [26], multi-scale models of innate immune response in tumoural conditions [27], etc.  
51 An important computational model of macrophage polarization was able to detect 4 different M2  
52 subgroups of macrophages, as a result of various combinations of pro- and anti-inflammatory  
53 extra-cellular signals [26], using exclusively literature-based knowledge on the intra-cellular regulatory  
54 interactions and pathways involved in the polarization process. Nevertheless, many important  
55 questions remain to be explored regarding the polarization states, especially in a tumour setting. More  
56 specifically, it is important to identify the pathways involved in TAM formation and to understand to  
57 what extent the macrophage plasticity facilitates this process in a TME. On the other hand, despite  
58 the wealth of quantitative information from bulk and single-cell sequencing datasets, the inference of  
59 regulatory networks based on experimental data remains a difficult challenge, with most approaches  
60 proposing a combination of both literature- and data-driven methods [28–30].

61 In Chronic Lymphocytic Leukemia (CLL), a B-cell malignancy in which patients accumulate  
62 large quantities of malignant CLL cells in their lymph nodes, an interesting ecology of cancer cells  
63 and immune cells is established. CLL cells are able to educate surrounding monocytes, through  
64 direct contact and cytokine signals, turning them into TAMs, which in this disease are referred to  
65 as Nurse Like Cells (NLCs) [31]. NLCs are derived from CD14<sup>+</sup> monocytes and are characterised  
66 by a distinct set of antigens (CD14lo, CD68hi, CD11b, CD163hi) [32,33]. Moreover, NLCs express  
67 stromal-derived-factor-1alpha, a chemokine which promotes chemotaxis and activates mitogen  
68 activated protein kinases, ultimately leading to more aggressive cancers and better survival of these  
69 cells *in-vitro*. Through direct contact, the NLCs are able to protect the cancer CLL cells from apoptotic  
70 signals, and stimulate environment mediated drug resistance. Interactions between NLCs and CLL  
71 cells appear to be mediated by the B cell receptor, which, when stimulated, activates production of  
72 CCL3/4, initiating the recruitment of other cells, including CD4<sup>+</sup> T cells and more NLCs. Another  
73 pathway that has been associated with NLCs and TAMs more in general is that of CSF-1 (MCSF).  
74 Patients with high expression of this factor usually show faster CLL progression and this gene was  
75 implicated in the production of NLCs. Also the more M1- or M2-like profile of NLCs in specific patients  
76 correlates with active and controlled disease, respectively. Analyses of the transcriptomic profile of  
77 NLCs suggest their high similarity to the macrophage M2 profile described in solid tumours, which  
78 makes studying the formation of NLCs all the more relevant in the quest of controlling TAMs in other  
79 malignancies.

80 NLC formation can be studied through an *in-vitro* system in which heterologous co-cultures  
81 of healthy monocytes and patient-derived CLL cells can be established to produce NLCs in  
82 absence of any other cell type. This system is particularly suited to mathematical modelling, as  
83 experimental conditions are well controlled and the cell types present are limited to  
84 monocytes/macrophages and cancer cells, without the confounding effects of immune or other  
85 healthy cells.

86 Boolean models are discrete dynamical models, in which each component (gene, transcription  
87 factor, chemokine, cytokine, receptor, etc.) is associated with a discrete (binary) variable, representing  
88 its concentration, activity or expression. Despite the complex processes relating the transcription of  
89 a gene into an mRNA and its subsequent translation into a protein with possibly post-translational  
90 modifications, in this paper we consider a single node for gene, mRNA and protein, such that a link  
91 between two transcription factors signifies that one of them affects transcription of the gene of the other.  
92 The future states of each component are determined by the current states of its regulators, as given by  
93 a Boolean function that represents the regulatory relationships between the components according to  
94 the logic operators AND, OR and NOT. The *state* of the system at each time point is given by a binary  
95 vector, in which each element represents the state of the corresponding component (ON/OFF) [23,34].  
96 Starting from an initial state, as time passes the system will follow a trajectory of states reaching one of  
97 many attractors that can be a single stable state (fixed point) or a set of recurrent states (limit cycle).  
98 Attractors usually represent specific phenotypes, such as cellular differentiated states, cell cycle states,  
99 etc. Despite their coarse-grained description, Boolean models have been successfully used to capture  
100 real-world biological features like, for example, the mechanisms of cell fate decision [35], hierarchical  
101 differentiation of myeloid progenitors [36], dynamical modelling of oncogenic signalling [37], amongst  
102 many other applications [38–40]. One of their main advantages is the simplicity of performing *in-silico*  
103 experiments simulating a variety of mutant and knockout conditions, and the possibility of obtaining  
104 qualitative or semi-quantitative results without requiring experimentally-derived parameter values, as  
105 needed by differential equations. Starting from a pathway diagram describing a biological process,  
106 and adding logic rules, Boolean models allow us to model the process, uncover the main regulators,  
107 and run simulations.

108 Understanding the mechanisms of TAM formation is of particular interest because of their  
109 pro-tumoural activity which hampers T cell cytotoxic activity. In this study, we therefore follow two  
110 lines of enquiry: (i) we reconstruct a macrophage polarization regulatory network using literature and  
111 extend it based on transcriptomic data from an *in-vitro* model of NLC formation, (ii) we implement a  
112 Boolean model of monocyte differentiation into NLC simulating these *in-vitro* cultures.

## 113 2. Results

### 114 2.1. Reconstruction of the regulatory network leading to NLC formation

115 To reconstruct the gene regulatory network (GRN) governing the formation of NLCs, we  
116 started from a previous macrophage polarization GRN [26] and extended it in order to include  
117 specific extracellular signals found in the Chronic Lymphocytic Leukaemia (CLL) context and other  
118 intra-cellular components involved in NLC formation. The network extension was based on extensive  
119 literature review and transcription factor (TF) activities estimation for each phenotype. Briefly, we  
120 used transcriptomics data for monocytes, M1, M2 and NLCs to calculate the TF activities in each  
121 condition, and chose the TF with the highest activities in each phenotype (see Methods, Section 5.3).  
122 For NLCs, we identified specific TFs using a set of 17 microarray expression profiles [33], which  
123 interestingly have higher activities than in M1 and M2. Particularly, HMGB1 and HIF1 are linked to  
124 the pro-tumoural activity of NLC (Appendix), and were considered as key regulators that determine  
125 the distinct phenotypes between M2 and NLC.

126 The main characteristics of these 3 types of macrophages are given in Table 1. A short description  
127 of the profiles for the main macrophage phenotypes is given in Appendix, however, a detailed

**Table 1.** The main characteristics of M1, M2 and NLC phenotypes according to (i) activators, (ii) secreted cytokines or expressed genes, and (iii) functions in tumoural environments (see [Appendix](#)).


	<b>M1</b>	<b>M2</b>	<b>NLC</b>
<b>Activated by</b>	IFN $\gamma$ LPS	Immune complexes IL-4 IL-13 IL-10	IL-10 TGF- $\beta$ CSF-1
<b>Secrete</b>	Th1 inducing cytokines TNF $\alpha$ IL-12 IL-18 IFN $\alpha/\beta$ IL-1 $\beta$ IL-6	IL-10 TGF- $\beta$ VEGF EGF	IL-10 TGF- $\beta$ IL-1Ra HIF1/2 PD-L1; B7-H4; TNFSF13/B; VEGF chemokines: CXCL12, CXCL13
<b>Function</b>	<b>Anti-tumoural activity:</b> releasing nitric oxide (NO); presenting tumour antigens to CD4+ Th1 cells; driving the activity of cytotoxic CD8+ T cells at the tumour site	<b>Anti-inflammatory processes:</b> Th2 responses(M2a); Downregulation of immune response (M2b); matrix deposition and tissue remodelling (M2c)	<b>Promote tumour growth:</b> secretion of soluble immunosuppressive agents; expression of contact-dependent immunosuppressive receptors (PD-L1, B7-H4) leading to enhancing CD8+ T cell infiltration high levels of HIF1 and HIF2 which leads to expression of genes associated with pro-tumoural activity
<b>References</b>	[1,41–43]	[1–3,43]	[12,13,17,42,44]

128 explanation of the mechanisms, pathways and components involved in the polarization process can be  
129 found in the cited papers and the references therein.

130 The inferred regulatory network of macrophage polarization is given in [Figure 1](#). It contains 10  
131 extracellular signals, 30 intra-cellular components, most of them being TFs and interleukins, and 3  
132 outputs, which are used as readouts, namely M1 polarization, M2 polarization and NLC. Pathway  
133 enrichment analysis [45] showed that most of the components are involved in the JAK-STAT signalling  
134 pathway, pathways related to cancer, Th17 cell differentiation, cytokine receptor interaction and other  
135 inflammatory conditions.

## 136 2.2. A Boolean model of macrophage polarization

137 Starting from the regulatory network in [Figure 1](#), the Boolean functions for each component are  
138 given in [Table 2](#). Here, the Boolean functions were based on published experimental evidence from the  
139 literature. The numerical simulations were performed considering all the possible initial intracellular  
140 conditions and combinations of stimuli, while applying the synchronous updating method to calculate  
141 the system's attractors (section 5.1). The simulation results show that the system reaches 1384 fixed  
142 point attractors, while other cyclic attractors of length 2 and 3 were also present. For our scope, in the  
143 following paragraphs we focus only on the fixed point attractors. It is important to note that fixed point  
144 attractors are time invariant, i.e. the number of fixed points is not affected from the updating method  
145 chosen, while the number of cyclic attractors and their characteristics (period, basin of attraction)  
146 depend on the updating method (section 5.1). Here and throughout the paper, we will refer to an  
147 attractor as the binarized expression profile which we assign to a polarization state (or a phenotype). To  
148 attribute the attractors to certain phenotype categories, we removed all the input nodes (extracellular  
149 signals) from the attractors, thus reducing the attractors' space to 214 fixed points.



**Figure 1.** The regulatory network of macrophage polarization: Nodes in green represent the extra-cellular signals, classified as M1, M2 and NLC inducers; nodes in purple represent receptors in the macrophage membrane, usually activated upon contact with cells in the outer environment; nodes in yellow represent the transcription factors and chemokines involved in the polarization process, as an intermediate step or as an output. The interactions between components can be either activation (black) or inhibition (red). The dashed arrows indicate indirect effects, in which the targets are the end-products, i.e. intermediate interactions are involved but not represented in the network.

**Table 2.** Boolean rules of the 30 intra-cellular nodes of the macrophage polarization network

Node	Boolean function
IFNGR	IFNG or IFNAB and not (SOCS1)
CSF2RA	GMCSF
IL1R	IL1 or IL1b
TLR4	LPS and not (FCGR)
FCGR	IC and (LPS or IL1)
IL4RA	IL4 and IL13
IL10R	IL10 or IL10s <sup>1</sup>
MCSFR	MCSF(also known as CSF-1)

<sup>1</sup> secreted

**Table 2.** Boolean rules of the 30 intra-cellular nodes of the macrophage polarization network

Node	Boolean function
STAT1	IFNGR or STAT1 and not (STAT6)
STAT5	(CSF2RA and not (STAT3 or IRF4)
NFKB	(STAT1 or TNFA or TLR4 or IL1R) and not (STAT6 or FCGR or PPARG or KLF4)
PPARG	IL4RA or MCSFR or ERK and not (STAT6)
STAT6	IL4RA or MCSFR
JMJD3	IL4RA or MCSFR
STAT3	(IL10R or EGF or STAT3) and not (FCGR or PPARG)
IRF3	TLR4
ERK	FCGR
KLF4	STAT6
SOCS1	STAT6 or STAT1
IRF4	JMJD3
IRF5	STAT5 and not (IRF4)
IL1b	NFKB or TNFA
IFNAB	IRF3
EGF	ERK or STAT3
IL12	STAT1 or STAT5 or NFKB
IL10s	(PPARG or STAT3) and not (IRF5 or TNFA)
TNFA	IRF5 and not (IL10s)
TGFB	STAT3 and (not TNFA)
HIF1A	(STAT3 or IL10s) and (not STAT1)
RAGE	HMGB1

### 150 2.3. Phenotype identification through interpretation of the attractors

151 The large attractors' space raises the challenge of interpreting its biological meaning. To categorize  
 152 the attractors in specific polarization states, two different methods were used: 1) a supervised  
 153 literature-based method using the expression profiles of the macrophage phenotypes taken from  
 154 the literature, and 2) an unsupervised method grouping attractors based on their similarity and then  
 155 applying clustering algorithms to assign them to specific phenotypes.


#### 156 2.3.1. Interpreting attractors based on a supervised method

157 To identify the main phenotypes detected by the model, we categorized all the attractors according  
 158 to the expression profiles of M1, M2 and NLC known from the literature, as described in [Table 1](#) and  
 159 [Appendix](#):

- 160 • M1: IL-12, NF- $\kappa$ B, TNF $\alpha$  and STAT1 or STAT5 active;
- 161 • M2: IL-10, STAT3 or STAT6, PPAR $\gamma$  active;
- 162 • NLC: TGF $\beta$ , HIF1 $\alpha$ , EGF, RAGE active;
- 163 • M0: M0 attractors + Attractors not falling in any of the above categories.

164 It is important to note that the M1, M2 and NLC categories were considered as mutually exclusive;  
 165 therefore the rest of the attractors were categorized together with M0, in a category apart that includes  
 166 all the attractors exhibiting characteristics of both M1 and M2 phenotypes, or corresponding to  
 167 states without biological significance. Interestingly, we found that most of the attractors fall into  
 168 the M2 ( $\approx 67.3\%$ ) category, followed by the M1 ( $\approx 4.7\%$ ) category and NLC ( $\approx 2\%$ ) subset ([Figure](#)  
 169 [2](#)), indicating the high likelihood for the system to reach one of the anti-inflammatory polarization  
 170 states. The similarities between attractors falling in each category were estimated by calculating the


171 Jaccard-Needham distances ( $\text{dist\_values} \in [0, 0.5]$ ). Considering the low values of binary distances  
 172 between attractors in each category, we then calculated the average attractor states (Figure 2 (b)-(e)).  
 173 Importantly, we observe that these averaged attractors largely correspond to the expected expression  
 174 profiles for M1, M2 and NLC defined above. A principal component analysis shows the main identified  
 175 clusters of attractors corresponding to each phenotype (Figure 3). From the plot, we can easily observe  
 176 that NLC attractors are not well separated from M0, which can be explained considering that a large  
 177 number of attractors in our M0 category have profiles intermediate between M1 and M2 and NLCs are  
 178 also thought to have an intermediate profile.



**Figure 2.** (a) Heatmap of 214 attractors. (b)-(e) Averaged attractors for each category: M0, M1, M2 and NLC.

### 179 2.3.2. Interpreting attractors based on an unsupervised method

180 Alongside with the supervised method, we also performed unsupervised clustering on the  
 181 attractor space, in order to investigate whether the main phenotypes we expect in this system can be



**Figure 3.** PCA of 214 attractors: M1 and M2 attractors are observed in distinct clusters, while NLC attractors appear in between the two extremes of the polarization spectrum.


182 recovered in an unbiased way just exploring the structure of the attractors' space. We hypothesise  
183 that the attractors corresponding to the same phenotype category will be characterized by a small  
184 binary distance and consequently will fall into the same cluster. To this end, we first estimated the  
185 similarity among the attractors by calculating the Jaccard-Needham distance [46]. We then applied  
186 hierarchical density based clustering on the Jaccard-Needham distances (Figure 4) to identify the main  
187 attractor clusters. As can be seen from the heatmap, 5 main clusters are detected: one of them (Cluster  
188 4) corresponds to the zero-attractors (attractor 1: all the components in OFF state, attractor 2: all the  
189 components in OFF state, except from  $expr_{RAGE} = 1$ ) and it was not considered for further analysis. A  
190 closer look at the averages of the attractors falling in each cluster highlights the detected expression  
191 profiles (Figure 4 (b)-(e)). Based on the averaged expression profiles of attractors in each cluster, we  
192 observe a clear representation of M1, M2 and NLC phenotypes, respectively Cluster 5  $\rightarrow$  M1: IL-12,  
193 IL-1R, NF- $\kappa$ B, STAT1, TNF $\alpha$  highly expressed, Cluster 2  $\rightarrow$  M2: IL-10, IL-10R, JMJD3, KLF4, IRF4,  
194 PPAR $\gamma$  and STAT6 highly expressed, and Cluster 3  $\rightarrow$  NLC: EGF, HIF1 $\alpha$ , RAGE, TGF $\beta$  and IL-10  
195 highly expressed. Considering the high expression of both M1, M2 and NLC components, we attribute  
196 Cluster 1 to M0.

### 197 2.3.3. Robustness of attractor interpretation independent of annotation method

198 While choosing between supervised and unsupervised methods one must consider some  
199 advantages and disadvantages. Supervised approaches can ensure a specific match between the  
200 observed attractors and prior biological knowledge of each phenotype, which can be an issue when the  
201 attractors can correspond to uncharacterised biological states and can be limited to the use of existing  
202 knowledge. On the other hand, unsupervised methods offer the simplicity of detecting the different  
203 state categories in a more unbiased way and possibly to identify unknown intermediate phenotypes in  
204 the polarization spectrum of the macrophages.



205 For a more quantitative comparison between the supervised and the unsupervised methods,  
 206 we calculated the Pearson correlation coefficient between the averaged expression profiles obtained  
 207 from each phenotype and each cluster (Figure 5). Our results show the accuracy of the unsupervised  
 208 method in capturing the M1 ( $corr\_coeff = 0.92$ ), M2 ( $corr\_coeff = 1$ ) and NLC ( $corr\_coeff =$   
 209  $0.91$ ) phenotypes, while the M0 category matches best with Cluster 1 with  $corr\_coeff = 0.97$ , not  
 210 corresponding to any phenotype.



**Figure 4.** (a) Heatmap of Jaccard-Needham distances of 214 attractors: 5 main clusters can be observed. Cluster 4 contains the attractor with all nodes in the OFF state and was not considered for further analysis. (b)-(e) Averaged attractors for each cluster in (a).

	Categories			
	M0	M1	M2	NLC
Cluster 1	0.97	0.4	-0.13	0.39
Cluster 2	-0.15	-0.47	1	-0.13
Cluster 3	0.56	-0.29	-0.02	0.91
Cluster 5	0.52	0.92	-0.37	-0.07

**Figure 5.** Matrix of Pearson correlation between M0, M1, M2 and NLC categories and the 4 biologically relevant clusters.

### 211 3. Model validation through *in-silico* perturbations

212 To validate the model, we performed several simulations mimicking specific environmental  
213 conditions consisting of M1, M2 or NLC signals only. Previous wet-lab experiments have shown that  
214 in co-cultures of monocytes and CLL cells, the CLL signal will elicit the differentiation of monocytes  
215 into NLCs. We studied the attractor space in the presence of only CLL signals (M-CSF and HMGB1)  
216 while considering all the possible combinations of intra-cellular signals. We then hypothesised that the  
217 presence of only a specific phenotype signal inducer (M1, M2 or NLC) would shift the macrophages  
218 polarization towards the corresponding phenotype and performed different simulations setting the  
219 signals favouring a certain phenotype to the ON state. Indeed, our simulations showed that the  
220 presence of specific signals (grouped as M1, M2 and NLC signals) would activate certain pathways  
221 that subsequently lead to the corresponding polarization state. Table 3 recapitulates the simulations  
222 performed by selecting only specific stimuli, the observed attractors' categories, the expression profiles  
223 of each polarization state and the network representation of active/inactive nodes/edges under these  
224 conditions. Interestingly, we observed that while the presence of M1 and M2 signals leads to the  
225 activation of their corresponding phenotypes, NLC signals activate both M2 and NLC polarization  
226 states, which reinforces the shared pro-tumoural activity of both phenotypes in the TME.

227 Additionally, several experimental studies on the effects of mutants and knock-outs on  
228 macrophage polarization states have been previously published [47–50]. Here, we performed  
229 simulations of knock-outs, as summarized in Table 4. Analysing the attractors' space, we observed a  
230 complete loss of M2 phenotype in  $STAT6^{-/-}$ , IRF4-JMJD3 axis KO and a significant decrease of M2  
231 attractors in  $PPAR\gamma^{-/-}$  and  $IL-4R\alpha^{-/-}$ , a complete loss of M1 phenotype in  $IRF5^{-/-}$  and  $STAT5^{-/-}$ ,  
232 and a significant decrease in M1 attractors in  $STAT1^{-/-}$ . Additionally, we observed a complete loss  
233 of NLC phenotype in  $STAT3^{-/-}$  and  $EGF^{-/-}$ . These results show that our model recapitulates the  
234 experimental observations in mutant conditions, as well as polarization outputs in the presence of  
235 different extra-cellular signals.

### 236 4. Discussion

237 The results reviewed in the previous sections highlight the various ways in which network-based  
238 dynamic models can be used to recapitulate the known characteristics of biological systems, as  
239 well as to predict new behaviours in specific conditions. Particularly, despite their limitations to  
240 a qualitative description, Boolean models yield a comprehensive picture of a system's dynamics,

**Table 3.** Simulations of environmental signals consisting of M1-, M2- and NLC-inducing signals only.

Simulations	Attractors	Network representation
<p>M1 stimuli ON: IFN<math>\gamma</math>, GM-CSF, IL-1, LPS.</p> <p>Attractor category: 18 M0, 5 M1</p>		
<p>M2 stimuli ON: IC, IL-4, IL-13, IL-10.</p> <p>Attractor category: 6 M0, 1 M2</p>		
<p>NLC stimuli ON: M-CSF, HMGB1.</p> <p>Attractor category: 4 M0, 1 M2, 4 NLC</p>		

241 including all the attractors of the system and the effects of mutants. Here, our main focus lies in  
 242 identifying the mechanisms that trigger the formation of NLCs in Chronic Lymphocytic Leukaemia,  
 243 a macrophage polarization state distinct from the ones that can be obtained with monocyte *in-vitro*  
 244 differentiation. Despite a large body of work on macrophage polarization, the phenotypic profile and  
 245 formation of tumour associated macrophages have not been fully elucidated yet, due to the difficulty  
 246 of isolating these cells from tumours. For this reason, we extend a previously published Boolean  
 247 model of macrophage polarization [26], by including specific nodes (genes, transcription factors and  
 248 receptors) that characterise the NLC profile. We then apply Boolean rules to the regulatory network to

**Table 4.** *In-silico* experiments with knock-outs [50].

Knock-out	Expected effect on polarization	Model results
STAT6	Complete knock-out Loss of M2 [51]	Complete loss of M2 M1 and NLC attractors not affected
PPAR $\gamma$	Conditional knock-out Loss of M2 [49]	Decrease number of M2 attractors M1 and NLC attractors not affected
IL-4R $\alpha$	Conditional knock-out Loss of M2 [52]	Decrease number of M2 attractors M1 and NLC attractors not affected
IRF5	Complete knock-out Loss of M1 [53]	Complete loss of M1 M2 and NLC attractors not affected
STAT5	Complete knock-out Loss of M1 [54]	Complete loss of M1 M2 and NLC attractors not affected
IRF4 - JMJD3 axis	Complete knock-out Loss of M2 [55]	Complete loss of M2 M1 and NLC attractors not affected
<b>Other simulations</b>		
STAT3	Complete loss of NLC Increase of M1 attractors M2 attractors not affected	
EGF	Complete loss of NLC M1 and M2 attractors not affected	
STAT1	Significant loss of M1 M2 and NLC attractors not affected	

249 study the system's asymptotic behaviour, when starting from all the possible initial conditions. The  
 250 main macrophage polarization states (phenotypes) were matched to the attractors first by applying  
 251 constraints on the value of specific network components (literature-based constraints) and subsequently  
 252 using unsupervised clustering of the attractors according to their (binary) similarities. Importantly,  
 253 the model results show that the attractor categories obtained by both supervised and unsupervised  
 254 methods, qualitatively match the M1, M2 and NLC profiles, while highlighting specific characteristics  
 255 of NLCs that distinguish them from M2 macrophages. In addition, the unsupervised method, although  
 256 less accurate than the supervised approach in characterizing the phenotypes, was shown to correctly  
 257 separate the phenotypic profiles in the absence of any constraint or previous knowledge. Clustering  
 258 of attractors with more powerful techniques [56,57]) would make the unsupervised method suitable  
 259 especially in Boolean modelling of large networks for which prior biological knowledge is not available.

260 It is important to note that both the network extension and the Boolean functions were based on  
 261 extensive literature review, which raises the difficulty of literature-based network inference methods  
 262 for large regulatory networks. A more data-driven approach to network inference will be considered  
 263 for future work [58,59].

264 The ultimate test of the model presented would be to compare our *in-silico* signatures for the  
 265 different attractors with experimental data measuring the state of each of our model components,  
 266 possibly through transcriptomic or proteomic characterization of each cell type. However, the  
 267 multiple levels at which the state of a component can be experimentally determined (gene expression,  
 268 protein level, protein activation state) reduce our expectations for finding a clear match. Even for  
 269 the well-characterised biological processes of macrophage polarization, all experimentally derived  
 270 readouts of the different phenotypes come from the detection of proteins on cell membranes, leaving  
 271 gaps in our understanding and justifying the need for data-driven approaches.

272 Taken together, our model can describe macrophage polarization in different environments  
 273 and mutant conditions. The inflammatory and cancer environments are characterized by a complex  
 274 combination of stimuli, which drive the polarization process of monocytes towards specific macrophage  
 275 phenotypes. In our network, we include the most significant pro- and anti-inflammatory signals, as  
 276 well as important cytokines that are involved in NLC polarization, like CSF-1 (M-CSF in our model)

277 and HMGB1. Despite the specific characteristics of the tumour micro-environments in solid cancers  
278 compared to the *in-vitro* model considered here, we believe that common polarization pathways are  
279 also involved in the formation of tumour associated macrophages (TAMs) in solid tumours, which  
280 have so far been modeled with a stronger emphasis on the inter-cellular aspects than on the molecular  
281 details [60–62]. Further work will be needed to establish whether our model can be useful more  
282 generally in different cellular environments. Overall, we hope that our model will encourage new  
283 empirical investigations on the complex nature of cell-cell interactions in the TME and the role of  
284 TAMs in cancer prognosis and treatment.

## 285 5. Methods

### 286 5.1. Boolean model Implementation

287 In the Boolean model each component (gene/mRNA, protein, chemokine) is associated with a  
288 discrete (binary) variable, representing its concentration, activity or expression. Time is considered  
289 to be implicit and the future states of each component were determined by the current states of their  
290 regulators, given by a Boolean function of  $m_i = 1, 2, \dots, N$  regulators of component  $X_i$ . Each Boolean  
291 function represents the regulatory relationships between the components and is expressed via Boolean  
292 operators AND, OR and NOT. The state of the system at each time point is given by a binary vector,  
293 whose  $i$ th element represents the state of the component  $X_i$  [23,34]. The set of all possible states and  
294 their transitions can be represented by a state transition graph, in which the nodes are the system's  
295 states (represented as binary vectors) and the directed edges are the transitions between them. The  
296 exponential function between the number of components and the state space size makes the graphical  
297 representation possible for only small networks. In Boolean models time is discrete and implicit:  
298 starting from an initial state, the system will follow a trajectory of states and, because of the finite state  
299 space, it reaches an attractor (stable states or limit cycles). To evaluate the state of each node at each  
300 timestep, two main updating methods have been proposed [21,63]:

- 301 • *synchronous updating method*: at each time step, all the nodes are updated simultaneously, assuming  
302 that all the interactions in the system require the same time to occur. Importantly, the state space  
303 is characterized by non-overlapping basins of attractions.
- 304 • *asynchronous updating method*: at each time step, the updated nodes are chosen randomly (General  
305 Asynchronous, Random Asynchronous) or according to their *characteristic updating time*, while  
306 the system's state will be characterized by overlapping basins of attractions.

307 It is important to note that fixed point attractors are time invariant, i.e. do not depend on the updating  
308 method. Our network is composed of  $N = 40$  components and has  $2^{40}$  possible states. Choosing the  
309 synchronous update method we obtain all transitions between them and consider the final attractors.  
310 The model was implemented using the BoolNet [48] R package [64].

### 311 5.2. Calculating the attractor similarity matrix

312 Given  $\Omega$  a space of binary  $N$ -dimensional vectors  $Z$  defined as

$$Z = (z_1, z_2, \dots, z_N), z_i = \{0, 1\}, \forall i \in \{1, 2, \dots, N\} \quad (1)$$

313 we define  $\bar{Z} = 1 - Z$  to be the complement of the binary vector  $Z$ . For each set of binary vectors  
314  $Z_1, Z_2 \in \Omega$  let  $S_{ij}$  be the number of occurrences of matches, with  $i \in Z_1$  and  $j \in Z_2$  being in the  
315 corresponding positions. In this way  $S_{11}(Z_1, Z_2) = Z_1 \cdot Z_2$  and  $S_{00}(Z_1, Z_2) = \bar{Z}_1 \cdot \bar{Z}_2$ .  
316 Based on  $S_{ij}$ , different measures exist, to calculate the similarity/dissimilarity between two binary  
317 vectors [46]. For our purpose, we calculated the *Jaccard-Needham* measures, defined as follows:

$$S(Z_1, Z_2) = \frac{S_{11}}{S_{11} + S_{10} + S_{01}} \quad (\text{similarity}) \quad D(Z_1, Z_2) = \frac{S_{10} + S_{01}}{S_{11} + S_{10} + S_{01}} \quad (\text{dissimilarity}) \quad (2)$$

### 318 5.3. Calculating the transcription factor activities

319 Microarray data used in this publication were downloaded from the NCBI repository Gene  
320 Expression Omnibus (GEO) database. M1 and M2 Macrophages microarray data accession number is  
321 GSE5099. Our previously published NLC microarray dataset can be found under accession number  
322 GSE87813 and was processed as described in [33]. Raw microarray datasets were then normalized using  
323 the RMA (Robust Multi-arrays Average) normalization method and batch corrected. Transcription  
324 factors activities were estimated using the Dorothea R package. Dorothea is a TF-regulon interaction  
325 database giving each interaction a confidence level. Here, levels of confidence of interactions from A to  
326 E were taken into account. The VIPER algorithm was used to estimate TF activities based on Dorothea  
327 interactions and our expression data [65,66].

328 **Author Contributions:** Conceptualization, M.M. and V.P.; methodology, M.M. and V.P.; software, M.M. and  
329 M.M.-M.; resources, M.M., N.V., M.D., M.P., J.-J.F., L.Y. and V.P.; validation, M.M. and F.R.; data curation, F.R.;  
330 original draft preparation, M.M., V.P. and N.V.; review and editing, M.D., M.P., J.-J.F. and L.Y.

331 **Funding:** This research was funded by INSERM, the Fondation Toulouse Cancer Santé and Pierre Fabre Research  
332 Institute, as part of the Chair of Bioinformatics in Oncology of the CRCT.

333 **Acknowledgments:** The authors thank Alexis Coullomb, Ting Xie, Julien Pernet, Maria Fernanda Senosain Ortega  
334 and Julie Bordenave for advising and critical reading of the manuscript.

335 **Conflicts of Interest:** The authors declare no conflict of interest. The funders had no role in the design of the  
336 study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to  
337 publish the results.

## 338 Appendix A

### 339 Appendix A.1 M1 pathway

340 The M1-like pro-inflammatory polarization state is applied to pro-inflammatory macrophages and  
341 can be obtained upon stimulation of those cells with IFN $\gamma$  or LPS which cause release of Th1-inducing  
342 cytokines including tumour necrosis factor  $\alpha$  (TNF $\alpha$ ), IL-12, IL-6, IL-1 $\beta$ , IL-18 and IFN $\alpha/\beta$  [1,41,42].  
343 The M1 macrophages metabolism rely on oxidative glycolysis [67] and intrinsically their polarization  
344 is linked with activation of STAT1, IRF5 and NF- $\kappa$ B [68]. M1-like macrophages are linked in fighting  
345 bacterial infections and intracellular pathogens. Additionally they show potent anti-tumoural activity  
346 which manifests mainly through: (i) release of large amount of nitric oxide (NO), which in turn is able  
347 to kill the cancer cells as a result of DNA damage, disruption of mitochondrial activity and limitation  
348 of iron availability, and (ii) presentation of tumour antigens to CD4<sup>+</sup> Th1 cells and driving the activity  
349 of cytotoxic CD8<sup>+</sup> T cells at the tumour site [43].

### 350 Appendix A.2 M2 pathway

351 M2-like macrophages include a wide variety of phenotypes involved in resolving of the  
352 inflammation. The M2 activation can be induced by stimulation with IL-4, IL-13, immune complexes  
353 and IL-10. The anti-inflammatory and regenerative activity of M2 macrophages come from abundant  
354 release of IL-10, TGF- $\beta$ , VEGF and EGF [1,43]. M2 macrophages depend strongly on oxidative  
355 phosphorylation [67] and the main TFs driving their polarization-state are: STAT6, PPAR $\gamma/\delta$ , IRF4,  
356 JMJD3 [68]. Depending on the anti-inflammatory processes M2-like macrophages are involved in,  
357 they manifest diverse phenotypes including: M2a - Th2 responses and killing and encapsulation of  
358 parasites, M2b – immunoregulation, M2c – matrix deposition and tissue remodeling [1–3].

359 Tumor-associated macrophages belong to the group of cells that arise upon the contact with  
360 cancer cells and tumor microenvironment (TME). They can show characteristics of both M1 and M2  
361 state, nevertheless upon prolonged presence in the TME the M2 characteristic becomes prevalent.  
362 TAMs influence the properties and dynamics of TME, although the precise factors that promote TAM  
363 activation have yet to be elucidated, as each TME is characterized by unique physical and chemical  
364 conditions [13,43]. However, certain common features may be identified. For example, CSF1, IL-10

365 and TGF- $\beta$  released from tumour cells and Treg cells, are powerful promoters of TAM polarization,  
366 which in turn support tumour progression by various mechanisms, like: (i) secretion of soluble  
367 immunosuppressive agents (IL-10, TGF- $\beta$ , IL-1 $\beta$ ), (ii) expression of Immune Checkpoint Inhibitors  
368 (PD-L1, B7-H4), and (iii) high levels of hypoxia-inducible factor 1 and 2 (HIF1, HIF2) which leads to  
369 expression of genes associated with pro-tumoural activity [12,13,43,69].

370 In the context of Chronic Lymphocytic Leukaemia (CLL) it has been proposed that Nurse-like  
371 cells (NLC), which are specific form of TAMs identified in this malignancy, are polarized in response to  
372 CSF-1 and HMGB1 proteins released by CLL cancer cells. In turn NLCs can stimulate and protect CLL  
373 cells by antigen presentation which stimulates BCR signaling, and also by both direct contact through  
374 membrane proteins and release of soluble factors including: [42]

- 375 • **membrane proteins:** CD2 (interacts with LFA-3 expressed on CLL cells [70]), CD31 (ligand of  
376 CD38 expressed on CLL cells), BAFF, APRIL (both BAFF and APRIL can be also released as  
377 soluble factors) [42,70]
- 378 • **soluble factors:** BDNF [71], WNT5A [72], CXCL12, CXCL13, IL6/8, IL-10 [42].

## 379 References

- 380 1. Foey, A.D. Macrophages — Masters of Immune Activation, Suppression and Deviation. *Immune Response*  
381 *Activation* **2014**. doi:10.5772/57541.
- 382 2. Martinez, F.O.; Gordon, S. The M1 and M2 paradigm of macrophage activation: Time for reassessment.  
383 *F1000Prime Reports* **2014**, *6*, 1–13.
- 384 3. Murray, P.J.; Wynn, T.A. Obstacles and opportunities for understanding macrophage polarization. *J.*  
385 *Leukoc. Biol.* **2011**, *89*, 557–563.
- 386 4. Mantovani, A.; Sica, A.; Locati, M. Macrophage polarization comes of age. *Immunity* **2005**, *23*, 344–346.  
387 doi:10.1016/j.immuni.2005.10.001.
- 388 5. Mosser, D.M.; Edwards, J.P. Exploring the full spectrum of macrophage activation. *Nature reviews*  
389 *immunology* **2008**, *8*, 958–969.
- 390 6. Locati, M.; Curtale, G.; Mantovani, A. Diversity, Mechanisms, and Significance of Macrophage Plasticity.  
391 *Annu. Rev. Pathol. Mech. Dis.* **2020**, *15*, 123–147. doi:10.1146/annurev-pathmechdis-012418-012718.
- 392 7. Gordon, S.; Martinez, F.O. Alternative activation of macrophages: Mechanism and functions. *Immunity*  
393 **2010**, *32*, 593–604. doi:10.1016/j.immuni.2010.05.007.
- 394 8. Ivashkiv, L.B. Epigenetic regulation of macrophage polarization and function. *Trends in immunology* **2013**,  
395 *34*, 216–223.
- 396 9. Cai, L.; Michelakos, T.; Deshpande, V.; Arora, K.S.; Yamada, T.; Ting, D.T.; Taylor, M.S.; Fernandez-del  
397 Castillo, C.; Warshaw, A.L.; Lillemo, K.D.; others. Role of tumor-associated macrophages in the clinical  
398 course of pancreatic neuroendocrine tumors (PanNETs). *Clinical Cancer Research* **2019**, *25*, 2644–2655.
- 399 10. Grossman, J.G.; Nywening, T.M.; Belt, B.A.; Panni, R.Z.; Krasnick, B.A.; DeNardo, D.G.; Hawkins, W.G.;  
400 Goedegebuure, S.P.; Linehan, D.C.; Fields, R.C. Recruitment of CCR2+ tumor associated macrophage  
401 to sites of liver metastasis confers a poor prognosis in human colorectal cancer. *Oncoimmunology* **2018**,  
402 *7*, e1470729.
- 403 11. Wynn, T.A.; Chawla, A.; Pollard, J.W. Macrophage biology in development, homeostasis and disease.  
404 *Nature* **2013**, *496*, 445–455.
- 405 12. Bingle, L.; Brown, N.; Lewis, C.E. The role of tumour-associated macrophages in tumour progression:  
406 implications for new anticancer therapies. *The Journal of Pathology: A Journal of the Pathological Society of*  
407 *Great Britain and Ireland* **2002**, *196*, 254–265.
- 408 13. Mantovani, A.; Marchesi, F.; Malesci, A.; Laghi, L.; Allavena, P. Tumour-associated macrophages as  
409 treatment targets in oncology. *Nature reviews Clinical oncology* **2017**, *14*, 399.
- 410 14. DeNardo, D.G.; Brennan, D.J.; Rexhepaj, E.; Ruffell, B.; Shiao, S.L.; Madden, S.F.; Gallagher, W.M.;  
411 Wadhvani, N.; Keil, S.D.; Junaid, S.A.; others. Leukocyte complexity predicts breast cancer survival and  
412 functionally regulates response to chemotherapy. *Cancer discovery* **2011**, *1*, 54–67.

- 413 15. Doedens, A.L.; Stockmann, C.; Rubinstein, M.P.; Liao, D.; Zhang, N.; DeNardo, D.G.; Coussens, L.M.;  
414 Karin, M.; Goldrath, A.W.; Johnson, R.S. Macrophage expression of hypoxia-inducible factor-1 $\alpha$  suppresses  
415 T-cell function and promotes tumor progression. *Cancer research* **2010**, *70*, 7465–7475.
- 416 16. Movahedi, K.; Laoui, D.; Gysemans, C.; Baeten, M.; Stangé, G.; Van den Bossche, J.; Mack, M.; Pipeleers,  
417 D.; In't Veld, P.; De Baetselier, P.; others. Different tumor microenvironments contain functionally distinct  
418 subsets of macrophages derived from Ly6C (high) monocytes. *Cancer research* **2010**, *70*, 5728–5739.
- 419 17. Larionova, I.; Kazakova, E.; Patysheva, M.; Kzhyskowska, J. Transcriptional, Epigenetic and Metabolic  
420 Programming of Tumor-Associated Macrophages. *Cancers* **2020**, *12*, 1411.
- 421 18. Ruffell, B.; Chang-Strachan, D.; Chan, V.; Rosenbusch, A.; Ho, C.M.; Pryer, N.; Daniel, D.; Hwang, E.S.;  
422 Rugo, H.S.; Coussens, L.M. Macrophage IL-10 blocks CD8+ T cell-dependent responses to chemotherapy  
423 by suppressing IL-12 expression in intratumoral dendritic cells. *Cancer cell* **2014**, *26*, 623–637.
- 424 19. Barabási, A.L.; Gulbahce, N.; Loscalzo, J. Network medicine: a network-based approach to human disease.  
425 *Nature reviews genetics* **2011**, *12*, 56–68.
- 426 20. Gulfidan, G.; Turanli, B.; Beklen, H.; Sinha, R.; Arga, K.Y. Pan-cancer mapping of differential protein-protein  
427 interactions. *Scientific reports* **2020**, *10*, 1–12.
- 428 21. Albert, I.; Thakar, J.; Li, S.; Zhang, R.; Albert, R. Boolean network simulations for life scientists. *Source code*  
429 *for biology and medicine* **2008**, *3*, 1–8.
- 430 22. Kervizic, G.; Corcos, L. Dynamical modeling of the cholesterol regulatory pathway with Boolean networks.  
431 *BMC systems biology* **2008**, *2*, 99.
- 432 23. Saadatpour, A.; Wang, R.S.; Liao, A.; Liu, X.; Loughran, T.P.; Albert, I.; Albert, R. Dynamical and structural  
433 analysis of a t cell survival network identifies novel candidate therapeutic targets for large granular  
434 lymphocyte leukemia. *PLoS Computational Biology* **2011**, *7*.
- 435 24. Naldi, A.; Carneiro, J.; Chaouiya, C.; Thieffry, D. Diversity and plasticity of Th cell types predicted from  
436 regulatory network modelling. *PLoS Comput Biol* **2010**, *6*, e1000912.
- 437 25. Alves, R.; Heiner, M.; Hiroi, N.; Chaouiya, C.; Abou-Jaoudé, W.; Traynard, P.; Monteiro, P.T.;  
438 Saez-Rodriguez, J.; Helikar, T.; Thieffry, D. Logical Modeling and Dynamical Analysis of Cellular Networks.  
439 *Frontiers in Genetics* | [www.frontiersin.org](http://www.frontiersin.org) **2016**, *1*, 94. doi:10.3389/fgene.2016.00094.
- 440 26. Palma, A.; Jarrah, A.S.; Tieri, P.; Cesareni, G.; Castiglione, F. Gene regulatory network modeling of  
441 macrophage differentiation corroborates the continuum hypothesis of polarization states. *Frontiers in*  
442 *physiology* **2018**, *9*, 1659.
- 443 27. Kondratova, M.; Czerwinska, U.; Sompairac, N.; Amigorena, S.D.; Soumelis, V.; Barillot, E.; Zinovyev,  
444 A.; Kuperstein, I. A multiscale signalling network map of innate immune response in cancer reveals cell  
445 heterogeneity signatures. *Nature communications* **2019**, *10*, 1–13.
- 446 28. Razzaq, M.; Paulevé, L.; Siegel, A.; Saez-Rodriguez, J.; Bourdon, J.; Guziolowski, C. Computational  
447 discovery of dynamic cell line specific Boolean networks from multiplex time-course data. *PLoS*  
448 *computational biology* **2018**, *14*, e1006538.
- 449 29. Martin, S.; Zhang, Z.; Martino, A.; Faulon, J.L. Boolean dynamics of genetic regulatory networks inferred  
450 from microarray time series data. *Bioinformatics* **2007**, *23*, 866–874.
- 451 30. Maetschke, S.R.; Madhamshettiwar, P.B.; Davis, M.J.; Ragan, M.A. Supervised, semi-supervised and  
452 unsupervised inference of gene regulatory networks. *Briefings in bioinformatics* **2014**, *15*, 195–211.
- 453 31. Burger, J.A.; Tsukada, N.; Burger, M.; Zvaifler, N.J.; Dell'Aquila, M.; Kipps, T.J. Blood-derived  
454 nurse-like cells protect chronic lymphocytic leukemia B cells from spontaneous apoptosis through stromal  
455 cell-derived factor-1. *Blood, The Journal of the American Society of Hematology* **2000**, *96*, 2655–2663.
- 456 32. Tsukada, N.; Burger, J.A.; Zvaifler, N.J.; Kipps, T.J. Distinctive features of “nurselike” cells that differentiate  
457 in the context of chronic lymphocytic leukemia. *Blood, The Journal of the American Society of Hematology* **2002**,  
458 *99*, 1030–1037.
- 459 33. Boissard, F.; Fournie, J.; Quillet-Mary, A.; Ysebaert, L.; Poupot, M. Nurse-like cells mediate ibrutinib  
460 resistance in chronic lymphocytic leukemia patients. *Blood cancer journal* **2015**, *5*, e355–e355.
- 461 34. Abou-Jaoudé, W.; Traynard, P.; Monteiro, P.T.; Saez-Rodriguez, J.; Helikar, T.; Thieffry, D.; Chaouiya, C.  
462 Logical modeling and dynamical analysis of cellular networks. *Frontiers in genetics* **2016**, *7*, 94.
- 463 35. Lawrence, T.; Natoli, G. Transcriptional regulation of macrophage polarization: Enabling diversity with  
464 identity. *Nature Reviews Immunology* **2011**, *11*, 750–761. doi:10.1038/nri3088.



- 465 36. Krumsiek, J.; Marr, C.; Schroeder, T.; Theis, F.J. Hierarchical differentiation of myeloid progenitors is  
466 encoded in the transcription factor network. *PLoS ONE* **2011**, *6*.
- 467 37. G.T. Zañudo, J.; Steinway, S.N.; Albert, R. Discrete dynamic network modeling of oncogenic signaling:  
468 Mechanistic insights for personalized treatment of cancer, 2018. doi:10.1016/j.coisb.2018.02.002.
- 469 38. Emmrich, P.M.F.; Roberts, H.E.; Pancaldi, V. A Boolean gene regulatory model of heterosis and speciation.  
470 *BMC evolutionary biology* **2015**, *15*, 24.
- 471 39. Bloomingdale, P.; Niu, J.; Mager, D.E.; others. Boolean network modeling in systems pharmacology. *Journal*  
472 *of pharmacokinetics and pharmacodynamics* **2018**, *45*, 159–180.
- 473 40. Davidich, M.I.; Bornholdt, S. Boolean network model predicts cell cycle sequence of fission yeast. *PloS one*  
474 **2008**, *3*, e1672.
- 475 41. Orecchioni, M.; Ghosheh, Y.; Pramod, A.B.; Ley, K. Macrophage polarization: Different gene signatures in  
476 M1(Lps+) vs. Classically and M2(LPS-) vs. Alternatively activated macrophages. *Frontiers in Immunology*  
477 **2019**, *10*, 1–14.
- 478 42. ten Hacken, E.; Burger, J.A. Microenvironment interactions and B-cell receptor signaling in Chronic  
479 Lymphocytic Leukemia: Implications for disease pathogenesis and treatment. *Biochimica et Biophysica Acta*  
480 *- Molecular Cell Research* **2016**, *1863*, 401–413. doi:10.1016/j.bbamcr.2015.07.009.
- 481 43. Guttman, O.; C. Lewis, E. M2-like macrophages and tumor-associated macrophages: overlapping and  
482 distinguishing properties en route to a safe therapeutic potential. *Integrative Cancer Science and Therapeutics*  
483 **2016**, *3*, 554–561. doi:10.15761/icst.1000204.
- 484 44. Cassetta, L.; Pollard, J.W. Targeting macrophages: therapeutic approaches in cancer. *Nature Reviews Drug*  
485 *Discovery* **2018**, *17*, 887–904.
- 486 45. Ogata, H.; Goto, S.; Fujibuchi, W.; Kanehisa, M. Computation with the KEGG pathway database. *Biosystems*  
487 **1998**, *47*, 119–128.
- 488 46. Zhang, B.; Srihari, S.N. Properties of Binary Vector Dissimilarity Measures. *Non Journal* **2000**, p. 20 pp.  
489 doi:10.1117/12.473347.
- 490 47. De’Broski, R.H.; Hölscher, C.; Mohrs, M.; Arendse, B.; Schwegmann, A.; Radwanska, M.; Leeto, M.;  
491 Kirsch, R.; Hall, P.; Mossmann, H.; others. Alternative macrophage activation is essential for survival  
492 during schistosomiasis and downmodulates T helper 1 responses and immunopathology. *Immunity* **2004**,  
493 *20*, 623–635.
- 494 48. Müssel, C.; Hopfensitz, M.; Kestler, H.A. BoolNet—an R package for generation, reconstruction and  
495 analysis of Boolean networks. *Bioinformatics* **2010**, *26*, 1378–1380.
- 496 49. Chawla, A. Control of macrophage activation and function by PPARs. *Circulation research* **2010**,  
497 *106*, 1559–1569.
- 498 50. Murray, P.J. Macrophage polarization. *Annual review of physiology* **2017**, *79*, 541–566.
- 499 51. Rutschman, R.; Lang, R.; Hesse, M.; Ihle, J.N.; Wynn, T.A.; Murray, P.J. Cutting edge: Stat6-dependent  
500 substrate depletion regulates nitric oxide production. *The Journal of Immunology* **2001**, *166*, 2173–2177.
- 501 52. Vannella, K.M.; Barron, L.; Borthwick, L.A.; Kindrachuk, K.N.; Narasimhan, P.B.; Hart, K.M.; Thompson,  
502 R.W.; White, S.; Cheever, A.W.; Ramalingam, T.R.; others. Incomplete deletion of IL-4R $\alpha$  by LysM Cre  
503 reveals distinct subsets of M2 macrophages controlling inflammation and fibrosis in chronic schistosomiasis.  
504 *PLoS Pathog* **2014**, *10*, e1004372.
- 505 53. Dalmas, E.; Toubal, A.; Alzaid, F.; Blazek, K.; Eames, H.L.; Lebozec, K.; Pini, M.; Hainault, I.; Montastier,  
506 E.; Denis, R.G.; others. Irf5 deficiency in macrophages promotes beneficial adipose tissue expansion and  
507 insulin sensitivity during obesity. *Nature medicine* **2015**, *21*, 610–618.
- 508 54. Friedrich, J.; Heim, L.; Trufa, D.I.; Sirbu, H.; Rieker, R.J.; Chiriac, M.T.; Finotto, S. STAT1 deficiency supports  
509 PD-1/PD-L1 signaling resulting in dysfunctional TNF $\alpha$  mediated immune responses in a model of NSCLC.  
510 *Oncotarget* **2018**, *9*, 37157.
- 511 55. Satoh, T.; Takeuchi, O.; Vandenbon, A.; Yasuda, K.; Tanaka, Y.; Kumagai, Y.; Miyake, T.; Matsushita,  
512 K.; Okazaki, T.; Saitoh, T.; others. The Jmjd3-Irf4 axis regulates M2 macrophage polarization and host  
513 responses against helminth infection. *Nature immunology* **2010**, *11*, 936–944.
- 514 56. Murtagh, F.; Contreras, P. Algorithms for hierarchical clustering: an overview. *Wiley Interdisciplinary*  
515 *Reviews: Data Mining and Knowledge Discovery* **2012**, *2*, 86–97.
- 516 57. McInnes, L.; Healy, J.; Astels, S. hdbscan: Hierarchical density based clustering. *Journal of Open Source*  
517 *Software* **2017**, *2*, 205.

- 518 58. Eduati, F.; De Las Rivas, J.; Di Camillo, B.; Toffolo, G.; Saez-Rodriguez, J. Integrating literature-constrained  
519 and data-driven inference of signalling networks. *Bioinformatics* **2012**, *28*, 2311–2317.
- 520 59. Kulkarni, S.R.; Vandepoele, K. Inference of plant gene regulatory networks using data-driven methods: A  
521 practical overview. *Biochimica et Biophysica Acta (BBA)-Gene Regulatory Mechanisms* **2020**, *1863*, 194447.
- 522 60. Macklin, P.; Frieboes, H.B.; Sparks, J.L.; Ghaffarizadeh, A.; Friedman, S.H.; Juarez, E.F.; Jonckheere, E.;  
523 Mumenthaler, S.M. Progress towards computational 3-d multicellular systems biology. In *Systems Biology*  
524 *of Tumor Microenvironment*; Springer, 2016; pp. 225–246.
- 525 61. Margaris, K.; Black, R.A. Modelling the lymphatic system: challenges and opportunities. *Journal of the*  
526 *Royal Society Interface* **2012**, *9*, 601–612.
- 527 62. Galle, J.; Aust, G.; Schaller, G.; Beyer, T.; Drasdo, D. Individual cell-based models of the spatial-temporal  
528 organization of multicellular systems—Achievements and limitations. *Cytometry Part A: The Journal of the*  
529 *International Society for Analytical Cytology* **2006**, *69*, 704–710.
- 530 63. Albert, R.; Robeva, R. Signaling networks: Asynchronous boolean models. In *Algebraic and discrete*  
531 *mathematical methods for modern biology*; Elsevier, 2015; pp. 65–91.
- 532 64. Ihaka, R.; Gentleman, R. R: a language for data analysis and graphics. *Journal of computational and graphical*  
533 *statistics* **1996**, *5*, 299–314.
- 534 65. Holland, C.H.; Valdeolivas, A.; Saez-Rodriguez, J. TF activity inference from bulk transcriptomic data with  
535 DoRothEA as regulon resource.
- 536 66. Garcia-Alonso, L.; Holland, C.H.; Ibrahim, M.M.; Turei, D.; Saez-Rodriguez, J. Benchmark and integration  
537 of resources for the estimation of human transcription factor activities. *Genome research* **2019**, *29*, 1363–1375.
- 538 67. Geeraerts, X.; Bolli, E.; Fendt, S.M.; Van Ginderachter, J.A. Macrophage metabolism as therapeutic target  
539 for cancer, atherosclerosis, and obesity. *Frontiers in Immunology* **2017**, *8*, 289.
- 540 68. Wang, Z.; Brandt, S.; Medeiros, A.; Wang, S.; Wu, H.; Dent, A.; Serezani, C.H. MicroRNA 21 is a homeostatic  
541 regulator of macrophage polarization and prevents prostaglandin E 2-mediated M2 generation. *PloS one*  
542 **2015**, *10*, e0115855.
- 543 69. Heusinkveld, M.; van der Burg, S.H. Identification and manipulation of tumor associated macrophages in  
544 human cancers. *Journal of translational medicine* **2011**, *9*, 216.
- 545 70. Boissard, F.; Tosolini, M.; Ligat, L.; Quillet-Mary, A.; Lopez, F.; Fournié, J.J.; Ysebaert, L.; Poupot, M.  
546 Nurse-like cells promote CLL survival through LFA-3/CD2 interactions. *Oncotarget* **2017**, *8*, 52225.
- 547 71. Talbot, H.; Saada, S.; Barthout, E.; Gallet, P.F.; Gachard, N.; Abraham, J.; Jaccard, A.; Troutaud, D.; Lalloué,  
548 F.; Naves, T.; others. BDNF belongs to the nurse-like cell secretome and supports survival of B chronic  
549 lymphocytic leukemia cells. *Scientific reports* **2020**, *10*, 1–9.
- 550 72. Kipps, T.J.; Stevenson, F.K.; Wu, C.J.; Croce, C.M.; Packham, G.; Wierda, W.G.; O'Brien, S.; Gribben, J.; Rai,  
551 K. Chronic lymphocytic leukaemia. *Nature reviews Disease primers* **2017**, *3*, 1–22.